以递增式血液透析启动肾脏替代治疗:随机多中心临床试验方案
本方案描述一项随机前瞻性多中心开放标签临床试验,旨在评估以每周两次血液透析启动肾脏替代治疗是否比标准每周三次方案更好地保护残余肾功能。研究还探索尿毒症毒素浓度、透析剂量、贫血控制、营养状态、生活质量、住院和死亡等指标。仅纳入尿素清除率KrU≥2.5 mL/min/1.73 m²的初治血液透析患者,每组计划招募44例,随访至少1年,采用意向性治疗分析。
要点
- 每周两次递增式透析可能更好保护残余肾功能,但此前仅有观察性研究数据。
- 仅纳入KrU≥2.5 mL/min/1.73 m²的初治血液透析患者,排除无尿急性肾衰竭及移植失败后重返透析者。
- 每组44例、双侧α=0.05达到80%把握度,主要采用Kaplan-Meier和log-rank检验分析肾功能生存。
核心结论
- 递增式启动透析可能比常规治疗更好地保护残余肾功能,并具有相似或更高的生存率,但此前证据均来自观察性研究。
- 据研究者所知,这是首个评估每周两次血液透析启动肾脏替代治疗是否比标准每周三次方案更好保护残余肾功能的临床试验。
研究设计与样本
- 随机前瞻性多中心开放标签临床试验,比较每周两次与每周三次血液透析启动方案。
- 仅纳入尿素清除率KrU≥2.5 mL/min/1.73 m²的初治血液透析患者,排除无尿急性肾衰竭及肾移植失败后重返透析者。
- 每组计划招募44例,双侧均值比较α=0.05达到80%把握度,随访至少1年,按意向性治疗原则分析。
主要发现
- 研究将评估残余肾功能保护情况,并探索尿毒症毒素浓度、透析剂量、贫血控制、中分子尿毒症毒素清除、营养状态、生活质量、住院和死亡等指标。
- 采用Kaplan-Meier法估计两组肾功能生存概率,log-rank检验比较生存曲线,并以比例风险模型估计校正混杂因素后的风险比。
关键数值与推荐
- 纳入标准:初治血液透析患者,尿素清除率KrU≥2.5 mL/min/1.73 m²。
- 排除标准:无尿的急性肾衰竭患者,以及肾移植失败后重返血液透析的患者。
- 每组44例,双侧α=0.05,把握度80%。
- 最短随访1年,主要分析采用意向性治疗原则。
临床怎么用
- 对于仍保留一定残余肾功能的初治血液透析患者,可考虑以每周两次递增式透析启动,并随残余肾功能下降逐步增加剂量。
- 启动递增式透析前应评估尿素清除率KrU是否≥2.5 mL/min/1.73 m²,并排除无尿急性肾衰竭及移植失败后重返透析者。
局限性
- 原文为研究方案,尚未报告试验结果。
- 开放标签设计可能引入实施偏倚。
- 样本量按每组44例计算,检验效能基于双侧均值比较设定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrice-weekly haemodialysis is the usual dose when starting renal replacement therapy; however, this schedule is no longer appropriate since it does not consider residual renal function. Several reports have suggested the potential benefit of beginning haemodialysis less frequently and incrementally increasing the dose as the residual renal function decreases. However, all the data published so far are from observational studies. Thus, this clinical trial avoids any potential selection bias and will assess the possible benefits that have been observed in observational studies. METHODS/DESIGN: This report describes the study protocol of a randomized prospective multi-centre open-label clinical trial to evaluate whether starting renal replacement therapy with twice-weekly haemodialysis sessions preserves residual renal function better than the standard thrice-weekly regimen. We also explore other clinical parameters, such as concentrations of uremic toxins, dialysis doses, control of anaemia, removal of medium-weight uremic toxins, nutritional status, quality of life, hospital admissions and mortality. Only incident haemodialysis patients who can maintain a urea clearance rate KrU ≥ 2.5 mL/min/1.73 m2 are eligible. Patient recruitment began on 1 January 2017 and will last for 2 years or until the required sample size has been recruited to ensure the established statistical power has been reached. The minimum follow-up period will be 1 year. Anuric patients with acute renal failure and patients who return to haemodialysis after a kidney transplant failure are excluded. It has been calculated that 44 patients should be recruited into each group to achieve a power of 80% in a two-sided comparison of means with a usual significance level of 0.05. A time-to-event analysis will estimate the probability of kidney function survival in both groups using the Kaplan-Meier method. Survival curves will be compared with log-rank tests. This survival analysis will be complemented with a proportional hazard model to estimate the hazard ratio of kidney function survival adjusted for any confounding factors. Analyses will be carried out in accordance with the intention-to-treat principle. DISCUSSION: The incremental initiation of dialysis may preserve residual renal function better than the conventional treatment, with similar or higher survival rates, as reported by observational studies. To our knowledge, this is the first clinical trial to evaluate whether initiating renal replacement therapy with twice-weekly haemodialysis sessions preserves residual renal function better than beginning with the standard thrice-weekly regimen. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03302546. Registered on 5 October 2017.
引用
- Fernández Lucas M, Ruíz-Roso G, Merino JL, et al. Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial. Trials. 2020. PMID: 32075665. doi:10.1186/s13063-020-4058-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。